16 results on '"Ivanova, Mariia"'
Search Results
2. Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.
- Author
-
Ivanova, Mariia, Pescia, Carlo, Trapani, Dario, Venetis, Konstantinos, Frascarelli, Chiara, Mane, Eltjona, Cursano, Giulia, Sajjadi, Elham, Scatena, Cristian, Cerbelli, Bruna, d'Amati, Giulia, Porta, Francesca Maria, Guerini-Rocco, Elena, Criscitiello, Carmen, Curigliano, Giuseppe, and Fusco, Nicola
- Subjects
- *
BREAST tumor risk factors , *RISK assessment , *MEDICAL protocols , *CANCER relapse , *ARTIFICIAL intelligence , *EARLY detection of cancer , *CYTOCHEMISTRY , *TUMOR markers , *DECISION making in clinical medicine , *IMMUNOHISTOCHEMISTRY , *PATIENT-centered care , *DEEP learning , *ARTIFICIAL neural networks , *MACHINE learning , *ONCOLOGISTS , *INDIVIDUALIZED medicine , *MOLECULAR pathology , *HEALTH care teams , *ALGORITHMS , *DISEASE risk factors - Abstract
Simple Summary: Risk assessment in early breast cancer is critical for clinical decisions, but defining risk categories poses a significant challenge. The integration of conventional histopathology and biomarkers with artificial intelligence (AI) techniques, including machine learning and deep learning, has the potential to offer more precise information. AI applications extend beyond detection to histological subtyping, grading, and molecular feature identification. The successful integration of AI into clinical practice requires collaboration between histopathologists, molecular pathologists, computational pathologists, and oncologists to optimize patient outcomes. Effective risk assessment in early breast cancer is essential for informed clinical decision-making, yet consensus on defining risk categories remains challenging. This paper explores evolving approaches in risk stratification, encompassing histopathological, immunohistochemical, and molecular biomarkers alongside cutting-edge artificial intelligence (AI) techniques. Leveraging machine learning, deep learning, and convolutional neural networks, AI is reshaping predictive algorithms for recurrence risk, thereby revolutionizing diagnostic accuracy and treatment planning. Beyond detection, AI applications extend to histological subtyping, grading, lymph node assessment, and molecular feature identification, fostering personalized therapy decisions. With rising cancer rates, it is crucial to implement AI to accelerate breakthroughs in clinical practice, benefiting both patients and healthcare providers. However, it is important to recognize that while AI offers powerful automation and analysis tools, it lacks the nuanced understanding, clinical context, and ethical considerations inherent to human pathologists in patient care. Hence, the successful integration of AI into clinical practice demands collaborative efforts between medical experts and computational pathologists to optimize patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.
- Author
-
Ranghiero, Alberto, Frascarelli, Chiara, Cursano, Giulia, Pescia, Carlo, Ivanova, Mariia, Vacirca, Davide, Rappa, Alessandra, Taormina, Sergio Vincenzo, Barberis, Massimo, Fusco, Nicola, Rocco, Elena Guerini, and Venetis, Konstantinos
- Subjects
CIRCULATING tumor DNA ,METASTATIC breast cancer ,TISSUE analysis ,DISEASE progression ,BREAST cancer - Abstract
Breast cancer biomarker profiling predominantly relies on tissue testing (surgical and/or biopsy samples). However, the field of liquid biopsy, particularly the analysis of circulating tumour DNA (ctDNA), has witnessed remarkable progress and continues to evolve rapidly. The incorporation of ctDNA‐based testing into clinical practice is creating new opportunities for patients with metastatic breast cancer (MBC). ctDNA offers advantages over conventional tissue analyses, as it reflects tumour heterogeneity and enables multiple serial biopsies in a minimally invasive manner. Thus, it serves as a valuable complement to standard tumour tissues and, in certain instances, may even present a potential alternative approach. In the context of MBC, ctDNA testing proves highly informative in the detection of disease progression, monitoring treatment response, assessing actionable biomarkers, and identifying mechanisms of resistance. Nevertheless, ctDNA does exhibit inherent limitations, including its generally low abundance, necessitating timely blood samplings and rigorous management of the pre‐analytical phase. The development of highly sensitive assays and robust bioinformatic tools has paved the way for reliable ctDNA analyses. The time has now come to establish how ctDNA and tissue analyses can be effectively integrated into the diagnostic workflow of MBC to provide patients with the most comprehensive and accurate profiling. In this manuscript, we comprehensively analyse the current methodologies employed in ctDNA analysis and explore the potential benefits arising from the integration of tissue and ctDNA testing for patients diagnosed with MBC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis.
- Author
-
Sajjadi, Elham, Venetis, Konstantinos, Ivanova, Mariia, Noale, Marianna, Blundo, Concetta, Di Loreto, Eugenia, Scarfone, Giovanna, Ferrero, Stefano, Maggi, Stefania, Veronesi, Paolo, Galimberti, Viviana E., Viale, Giuseppe, Peccatori, Fedro A., Fusco, Nicola, and Guerini-Rocco, Elena
- Subjects
GESTATIONAL age ,TUMOR-infiltrating immune cells ,BREAST cancer ,CANCER diagnosis ,HORMONE receptors ,CANCER relapse - Abstract
Background: Breast cancer during pregnancy (PrBC) is a rare condition known for its aggressive clinical behavior. The presence of tumor-infiltrating lymphocytes (TILs) has been shown to have a significant impact on the prognosis of these patients. Despite some biological characteristics of the tumor that may differ depending on the gestational age, little is known about the dynamics of the immune landscape within the tumor microenvironment (TME) in PrBC. Therefore, in this study, our objective was to gain comprehensive insights into the relationship between gestational age at breast cancer diagnosis and the composition of the TME. Methods: n = 108 PrBC were selected from our institutional registry and categorized based on the gestational age by trimester. For all cases, TILs were profiled according to the International TILs Working Group recommendations, and subtyped by CD4, CD8, and forkhead box P3 (FOXP3) immunohistochemistry. PD-L1 was tested according to the combined positive score (CPS) using the IHC 22C3 pharmDx assay, with a cutoff value of ≥10 for positivity. The statistical approach encompassed Fisher’s and Chi-squared tests, with appropriate adjustments for multiple comparisons, logistic regression models, and survival analyses based on the Kaplan–Meier method. Results: The proportion of patients with poorly differentiated (G3) neoplasms increased as the gestational age advanced (first trimester, n = 25, 56.8%; second trimester, n = 27, 69.2%; third trimester, n = 21, 87.5%; p = 0.03). The histologic subtypes as well as the hormone receptor (HR) and HER2 status did not show significant changes across different pregnancy trimesters. In the HR+/HER2– subtype, there was a higher proportion of tumors with high/moderate TILs in the early phases of pregnancy, similar to FOXP3 expression (TILs: first trimester, n = 10, 35.7%; second trimester, n = 2, 10.5%; third trimester, n = 0; p = 0.02; FOXP3: first trimester, n = 10, 40%; second trimester, n = 3, 15.8%; third trimester, n = 0; p = 0.03). The median follow-up for our cohort was 81 months. Patients who relapsed after a breast cancer diagnosis during the first trimester were more frequently PD-L1-negative, unlike those with no disease recurrence (n = 9, 100% vs. n = 9, 56.3%; p = 0.03; hormone therapy and n = 9, 100% vs. n = 7, 53.9%; p = 0.02; chemotherapy). No statistically significant differences were seen among the three trimesters in terms of survival outcome. Conclusion: The TME dynamics of HR+/HER2− PrBC vary based on gestational age, suggesting that immune tolerance expression during later gestational age could explain the increased aggressiveness of tumors diagnosed at that stage. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods.
- Author
-
Porta, Francesca Maria, Sajjadi, Elham, Venetis, Konstantinos, Frascarelli, Chiara, Cursano, Giulia, Guerini-Rocco, Elena, Fusco, Nicola, and Ivanova, Mariia
- Subjects
TRIPLE-negative breast cancer ,HARBOR maintenance & repair ,TEST methods ,BIOMARKERS ,PROGNOSIS - Abstract
Triple-negative breast cancer (TNBC) poses a significant challenge in terms of prognosis and disease recurrence. The limited treatment options and the development of resistance to chemotherapy make it particularly difficult to manage these patients. However, recent research has been shifting its focus towards biomarker-based approaches for TNBC, with a particular emphasis on the tumor immune landscape. Immune biomarkers in TNBC are now a subject of great interest due to the presence of tumor-infiltrating lymphocytes (TILs) in these tumors. This characteristic often coincides with the presence of PD-L1 expression on both neoplastic cells and immune cells within the tumor microenvironment. Furthermore, a subset of TNBC harbor mismatch repair deficient (dMMR) TNBC, which is frequently accompanied by microsatellite instability (MSI). All of these immune biomarkers hold actionable potential for guiding patient selection in immunotherapy. To fully capitalize on these opportunities, the identification of additional or complementary biomarkers and the implementation of highly customized testing strategies are of paramount importance in TNBC. In this regard, this article aims to provide an overview of the current state of the art in immune-related biomarkers for TNBC. Specifically, it focuses on the various testing methodologies available and sheds light on the immediate future perspectives for patient selection. By delving into the advancements made in understanding the immune landscape of TNBC, this study aims to contribute to the growing body of knowledge in the field. The ultimate goal is to pave the way for the development of more personalized testing strategies, ultimately improving outcomes for TNBC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management.
- Author
-
Ivanova, Mariia, Porta, Francesca Maria, Giugliano, Federica, Frascarelli, Chiara, Sajjadi, Elham, Venetis, Konstantinos, Cursano, Giulia, Mazzarol, Giovanni, Guerini-Rocco, Elena, Curigliano, Giuseppe, Criscitiello, Carmen, and Fusco, Nicola
- Subjects
- *
METASTATIC breast cancer , *BREAST , *BRAIN metastasis , *COLONIZATION (Ecology) , *BLOOD-brain barrier , *BREAST cancer - Abstract
Breast cancer is the most frequently diagnosed malignancy worldwide and the leading cause of cancer-related death among women. Brain metastases are a primary contributor to mortality, as they often go undetected until late stages due to their dormant nature. Moreover, the clinical management of brain metastases is complicated by the relevant issue of blood-brain barrier penetration. The molecular pathways involved in the formation, progression, and colonization of primary breast tumors and subsequent brain metastases are diverse, posing significant hurdles due to the heterogeneous nature of breast cancer subtypes. Despite advancements in primary breast cancer treatments, the prognosis for patients with brain metastases remains poor. In this review, we aim to highlight the biological mechanisms of breast cancer brain metastases by evaluating multi-step genetic pathways and to discuss currently available and emerging treatment strategies to propose a prospective overview of the management of this complex disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Characterization of the immune environment in pregnancy-associated breast cancer.
- Author
-
Venetis, Konstantinos, Sajjadi, Elham, Ivanova, Mariia, Peccatori, Fedro Alessandro, Fusco, Nicola, and Guerini-Rocco, Elena
- Abstract
Pregnancy-associated breast cancer (PrBC) is a rare and clinically challenging condition. Specific immune mechanisms and pathways are involved in maternal–fetal tolerance and tumor-host immunoediting. The comprehension of the molecular processes underpinning this immune synergy in PrBC is needed to improve patients' clinical management. Only a few studies focused on the immune biology of PrBC and attempted to identify bona fide biomarkers. Therefore, clinically actionable information remains extremely puzzling for these patients. In this review article, we discuss the current knowledge on the immune environment of PrBC, in comparison with pregnancy-unrelated breast cancer and in the context of maternal immune changes during pregnancy. A particular emphasis is given to the actual role of potential immune-related biomarkers for PrBC clinical management. Pregnancy-associated breast cancer (PrBC) affects about 4% of women with breast cancer who are of childbearing age. Managing these tumors is difficult due to interactions between the mother, fetus and tumor. These interactions cause changes in the immune system of patients with PrBC. Understanding how the immune system responds to PrBC may lead to better ways of managing the disease. This review focuses on the current knowledge of the immune system in PrBC, including which components can be used as biomarkers to improve clinical management. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. The molecular landscape of breast mucoepidermoid carcinoma.
- Author
-
Venetis, Konstantinos, Sajjadi, Elham, Ivanova, Mariia, Andaloro, Silvia, Pessina, Simona, Zanetti, Chiara, Ranghiero, Alberto, Citelli, Gabriele, Rossi, Chiara, Lucioni, Marco, Malapelle, Umberto, Pagni, Fabio, Barberis, Massimo, Guerini‐Rocco, Elena, Viale, Giuseppe, and Fusco, Nicola
- Subjects
MUCOEPIDERMOID carcinoma ,PROGRAMMED death-ligand 1 ,TRIPLE-negative breast cancer ,CELL cycle regulation ,FLUORESCENCE in situ hybridization - Abstract
Mucoepidermoid carcinoma (MEC) of the breast is an extremely rare salivary gland‐type tumor characterized by epidermoid, basaloid, intermediate, and/or mucinous cells arranged in solid and cystic patterns. Despite their triple‐negative phenotype, breast MECs are generally considered low‐risk malignancies but their biology is largely unexplored; therefore, guidelines for clinical management are lacking. Here, we sought to characterize the molecular landscape of breast MECs. Thirteen cases were histologically reviewed, characterized for tumor‐infiltrating lymphocytes (TILs), and were subjected to immunohistochemistry for programmed death‐ligand 1 (PD‐L1, clone 22C3), EGFR, and amphiregulin (AREG). Rearrangements in MAML2 and EWSR1 were investigated by fluorescent in situ hybridization. Targeted next‐generation sequencing of 161 genes was performed on eight cases. Most MECs had low histological grade (n = 10, 77%), with the presence of TILs (n = 9/12; 75%) and PD‐L1 combined positive score ranging from 10 to 20 (n = 4/6; 67%). All cases showed EGFR and AREG overexpression and were fusion negative. Enrichment of genetic alterations was observed in PI3K/AKT/mTOR and cell cycle regulation pathways, while only one case harbored TP53 mutations. This is the first study providing extensive molecular data on breast MECs and the largest collection of cases available to date in the literature. Breast MECs lack TP53 mutations found in high‐grade forms of triple‐negative breast cancers and MAML2 or EWSR1 rearrangements pathognomonic of salivary MECs. Triple‐negativity and PD‐L1 positivity suggest a window of opportunity for immunotherapy in these patients. The EGFR/AREG axis activation, coupled with the mutational patterns in PI3K/AKT/mTOR and cell cycle pathways warrants caution in considering MECs as low‐risk neoplasms. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution.
- Author
-
Giugliano, Federica, Carnevale Schianca, Ambra, Corti, Chiara, Ivanova, Mariia, Bianco, Nadia, Dellapasqua, Silvia, Criscitiello, Carmen, Fusco, Nicola, Curigliano, Giuseppe, and Munzone, Elisabetta
- Subjects
ONCOGENES ,GENE expression ,BREAST tumors - Abstract
Simple Summary: Breast cancer is the most common cancer in women. Approximately 15% of breast cancers harbour an amplification of the ERBB2 gene and/or an overexpression of the HER2 protein and are thus classified as HER2-positive. However, HER2 protein expression could be heterogeneous, showing different patterns of spatial distribution. This feature, also called "spatial heterogeneity" may potentially affect treatment, response, and assessment of HER2 status, ultimately impacting the best treatment strategy. The activity of some new pharmacological agents, belonging to the group of antibody–drug conjugates, may represent an opportunity for overcoming this issue. In this review, we summarize the available evidence on HER2 heterogeneity and spatial distribution and how they may affect current available treatment choices. Approximately 15% of breast cancers are classified as HER2-positive, with an amplification of the ERBB2 gene and/or an overexpression of the HER2 protein. Up to 30% of HER2-positive breast cancers shows heterogeneity in HER2 expression and different patterns of spatial distribution, i.e., the variability in the distribution and expression of the HER2 protein within a single tumour. Spatial heterogeneity may potentially affect treatment, response, assessment of HER2 status and consequently, may impact on the best treatment strategy. Understanding this feature can help clinicians to predict response to HER2-targeted therapies and patient outcomes, and to fine tune treatment decisions. This review summarizes the available evidence on HER2 heterogeneity and spatial distribution and how this may affect current available treatment choices, exploring possible opportunities for overcoming this issue, such as novel pharmacological agents, belonging to the group of antibody–drug conjugates. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer.
- Author
-
Venetis, Konstantinos, Pepe, Francesco, Munzone, Elisabetta, Sajjadi, Elham, Russo, Gianluca, Pisapia, Pasquale, Ivanova, Mariia, Bonizzi, Giuseppina, Vacirca, Davide, Rappa, Alessandra, Ranghiero, Alberto, Taormina, Sergio Vincenzo, Viale, Giuseppe, Troncone, Giancarlo, Barberis, Massimo, Guerini-Rocco, Elena, Malapelle, Umberto, and Fusco, Nicola
- Subjects
NUCLEOTIDE sequencing ,REVERSE transcriptase polymerase chain reaction ,BREAST cancer ,SOMATIC mutation ,HORMONE receptors ,BREAST - Abstract
Somatic mutations in PIK3CA are present in ~40% breast cancers (BC); their detection in hormone receptor (HR)+/HER2− tumors allows for selecting patients with advanced disease eligible for PIK3CA targeting with alpelisib. The choice of what type of PIK3CA testing approach to adopt and which tissue sample to analyze is a new task in breast pathology. In this methodological study, we sought to assess the performance of next-generation sequencing (NGS) and RT-PCR for PIK3CA testing on archival formalin-fixed paraffin-embedded (FFPE) primary tumors and corresponding metastases. Sixteen HR+/HER2− BC with known PIK3CA-mutated status (ex. 7, 9, and 20) on metastatic samples by means of amplicon-based targeted NGS were selected, and n = 13 of these samples were re-tested with a commercially available CE-IVD RT-PCR assay. All available primary tumors (n = 8) were tested with both methods. NGS detected mutations in all samples, while RT-PCR in n = 2 sample-pairs and overall, in n = 5/8 (62.5%) primary tumors and 7/13 (53.8%) metastases (κ = 0.09; 95% CI, −0.69–0.87). Slight agreement (κ = 0; 95% CI, −0.59–0.59) was observed between NGS and RT-PCR, with the former being generally more sensitive in cases with low DNA quality and quantity. Post hoc visual inspection of the RT-PCR data increased the concordance to 76.9%. Targeted NGS offers reliable and robust PIK3CA testing on both tumor and metastasis FFPE samples; the accuracy of RT-PCR depends on the DNA quantity and quality. In HR+/HER2− BC, both the selection of the PIK3CA testing strategy of FFPE tissues and which sample to analyze should consider several technical parameters and should be tailored for each case. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Axillary Web Syndrome in Breast Cancer Women: What Is the Optimal Rehabilitation Strategy after Surgery? A Systematic Review.
- Author
-
Lippi, Lorenzo, de Sire, Alessandro, Losco, Luigi, Mezian, Kamal, Folli, Arianna, Ivanova, Mariia, Zattoni, Lorenzo, Moalli, Stefano, Ammendolia, Antonio, Alfano, Carmine, Fusco, Nicola, and Invernizzi, Marco
- Subjects
BREAST cancer ,ANALGESIA ,REHABILITATION ,RESISTANCE training ,MEDICAL rehabilitation ,SYNDROMES ,HEREDITARY cancer syndromes - Abstract
Background: Axillary web syndrome (AWS) is one of the most prevalent and underrecognized disorders affecting breast cancer (BC) women. However, the optimal therapeutic strategy to manage AWS is far from being fully characterized. Therefore, this systematic review aims to provide a broad overview of the available rehabilitation treatments in this burdensome condition. Methods: On 13 January 2022, PubMed, Scopus, Web of Science, Cochrane, and PEDro were systematically searched for clinical studies assessing rehabilitation interventions in post-surgical BC women with AWS. The outcomes analyzed were pain, AWS clinical resolution, upper limb function, and health-related quality of life (HR-QoL). Results: The search identified 1115 records, of which 11 studies were included. A total of 174 patients were assessed (ages ranging from 37 and 66 years old). The interventions included manual lymphatic drainage, manual therapy, stretching, resistance training, mobilization techniques, and Kinesio tape. Positive improvements were reported in terms of pain relief (in 7 studies), AWS clinical resolution (in 9 studies), upper limb function (in 10 studies), and HR-QoL (in 2 studies). Conclusions: Our findings suggest that rehabilitation might be considered an effective therapeutic strategy in AWS patients. Further RCTs are needed to characterize the optimal rehabilitative interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
- Author
-
Fusco, Nicola, Ivanova, Mariia, Frascarelli, Chiara, Criscitiello, Carmen, Cerbelli, Bruna, Pignataro, Maria Gemma, Pernazza, Angelina, Sajjadi, Elham, Venetis, Konstantinos, Cursano, Giulia, Pagni, Fabio, Di Bella, Camillo, Accardo, Marina, Amato, Michelina, Amico, Paolo, Bartoli, Caterina, Bogina, Giuseppe, Bortesi, Laura, Boldorini, Renzo, and Bruno, Sara
- Subjects
- *
PROGRAMMED death-ligand 1 , *COMPANION diagnostics , *TRIPLE-negative breast cancer , *PATHOLOGISTS , *METASTASIS - Abstract
Pembrolizumab has received approval as a first-line treatment for unresectable/metastatic triple-negative breast cancer (mTNBC) with a PD-L1 combined positive score (CPS) of ≥ 10. However, assessing CPS in mTNBC poses challenges. Firstly, it represents a novel analysis for breast pathologists. Secondly, the heterogeneity of PD-L1 expression in mTNBC further complicates the assessment. Lastly, the lack of standardized assays and staining platforms adds to the complexity. In KEYNOTE trials, PD-L1 expression was evaluated using the IHC 22C3 pharmDx kit as a companion diagnostic test. However, both the 22C3 pharmDx and VENTANA PD-L1 (SP263) assays are validated for CPS assessment. Consequently, assay-platform choice, staining conditions, and scoring methods can significantly impact the testing outcomes. This consensus paper aims to discuss the intricacies of PD-L1 CPS testing in mTNBC and provide practical recommendations for pathologists. Additionally, we present findings from a nationwide Italian survey elucidating the state-of-the-art in PD-L1 CPS testing in mTNBC. [Display omitted] • Breast pathologists face challenges in determining PD-L1 CPS score. • Lack of standardization across assays/staining platforms for PD-L1 CPS. • Validation and harmonization of the PD-L1 assays is crucial for consistent results. • Digital pathology may be of help, providing guidelines. • Infrastructures are present but challenges persist: harmonization, training. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. The molecular landscape of breast mucoepidermoid carcinoma
- Author
-
Konstantinos Venetis, Elham Sajjadi, Mariia Ivanova, Silvia Andaloro, Simona Pessina, Chiara Zanetti, Alberto Ranghiero, Gabriele Citelli, Chiara Rossi, Marco Lucioni, Umberto Malapelle, Fabio Pagni, Massimo Barberis, Elena Guerini‐Rocco, Giuseppe Viale, Nicola Fusco, Venetis, Konstantino, Sajjadi, Elham, Ivanova, Mariia, Andaloro, Silvia, Pessina, Simona, Zanetti, Chiara, Ranghiero, Alberto, Citelli, Gabriele, Rossi, Chiara, Lucioni, Marco, Malapelle, Umberto, Pagni, Fabio, Barberis, Massimo, Guerini-Rocco, Elena, Viale, Giuseppe, Fusco, Nicola, Venetis, K, Sajjadi, E, Ivanova, M, Andaloro, S, Pessina, S, Zanetti, C, Ranghiero, A, Citelli, G, Rossi, C, Lucioni, M, Malapelle, U, Pagni, F, Barberis, M, Guerini-Rocco, E, Viale, G, and Fusco, N
- Subjects
diagnosi ,Cancer Research ,breast cancer ,Oncology ,molecular profiling ,rare tumor ,triple-negative breast cancer ,biomarker ,Radiology, Nuclear Medicine and imaging ,mucoepidermoid carcinoma - Abstract
Mucoepidermoid carcinoma (MEC) of the breast is an extremely rare salivary gland-type tumor characterized by epidermoid, basaloid, intermediate, and/or mucinous cells arranged in solid and cystic patterns. Despite their triple-negative phenotype, breast MECs are generally considered low-risk malignancies but their biology is largely unexplored; therefore, guidelines for clinical management are lacking. Here, we sought to characterize the molecular landscape of breast MECs. Thirteen cases were histologically reviewed, characterized for tumor-infiltrating lymphocytes (TILs), and were subjected to immunohistochemistry for programmed death-ligand 1 (PD-L1, clone 22C3), EGFR, and amphiregulin (AREG). Rearrangements in MAML2 and EWSR1 were investigated by fluorescent in situ hybridization. Targeted next-generation sequencing of 161 genes was performed on eight cases. Most MECs had low histological grade (n = 10, 77%), with the presence of TILs (n = 9/12; 75%) and PD-L1 combined positive score ranging from 10 to 20 (n = 4/6; 67%). All cases showed EGFR and AREG overexpression and were fusion negative. Enrichment of genetic alterations was observed in PI3K/AKT/mTOR and cell cycle regulation pathways, while only one case harbored TP53 mutations. This is the first study providing extensive molecular data on breast MECs and the largest collection of cases available to date in the literature. Breast MECs lack TP53 mutations found in high-grade forms of triple-negative breast cancers and MAML2 or EWSR1 rearrangements pathognomonic of salivary MECs. Triple-negativity and PD-L1 positivity suggest a window of opportunity for immunotherapy in these patients. The EGFR/AREG axis activation, coupled with the mutational patterns in PI3K/AKT/mTOR and cell cycle pathways warrants caution in considering MECs as low-risk neoplasms.
- Published
- 2023
14. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
- Author
-
Morganti, Stefania, Marra, Antonio, Gandini, Sara, Ascione, Liliana, Ivanova, Mariia, Venetis, Konstantinos, Sajjadi, Elham, Zagami, Paola, Giugliano, Federica, Taurelli Salimbeni, Beatrice, Berton Giachetti, Pier Paolo Maria, Corti, Chiara, De Camilli, Elisa, Curigliano, Giuseppe, Fusco, Nicola, and Criscitiello, Carmen
- Subjects
- *
BREAST cancer prognosis , *EVALUATION of medical care , *METASTASIS , *CASE-control method , *CELL receptors , *ESTROGEN receptors , *DISEASE relapse , *LYMPHOCYTES , *PROGRESSION-free survival , *TUMOR markers , *BREAST tumors , *EVALUATION - Abstract
Estrogen receptor (ER) loss at metastatic relapse occurs in up to 20% of luminal-like primary breast tumors. Data about clinicopathological features associated with ER loss and its prognostic significance are limited. In a nested-case-control study, we compared clinicopathological characteristics and clinical outcomes between a cohort of 51 patients with primary ER+ /HER2- and paired triple-negative metastasis (LUM-TN) and two control cohorts of paired early-metastatic ER+ /HER2- (LUM-LUM, n = 50) and triple-negative (TN-TN, n = 49) breast cancers. Stromal tumor-infiltrating lymphocytes (TILs) were assessed according to the TILs Working Group recommendations as continuous and discrete variables with cutoffs (20%, 40%). LUM-TN tumors had lower ER expression than LUM-LUM tumors, but lower grade and Ki67 than TN-TN cases. Median distant-metastasis free survival was similar for LUM-TN and LUM-LUM cohorts, but significantly longer than in TN-TN cases (log-rank P < 0.001). LUM-TN and TN-TN cohorts had a comparable survival from the time of metastatic recurrence, which was significantly shorter than in patients with LUM-LUM tumors (log-rank P < 0.001). High TILs were associated with worse outcomes in patients with ER loss (P < 0.001). Breast tumors with ER loss at metastatic relapse have intermediate features and outcomes compared with metastatic luminal- like and ab initio triple-negative tumors. Further investigation on the biological mechanisms underpinning the loss of ER expression is ongoing. • ER loss is frequent among primary luminal- like breast tumors. • LUM-TN tumors had lower ER expression than LUM-LUM tumors. • Primary tumor grade and Ki67 are higher in tumors with ER loss than in ab initio TNBC • Outcome of LUM-TN tumors is intermediate between concordant LUM-LUM and TN-TN tumors. • High TILs are associated with worse outcomes in tumors with ER loss. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
- Author
-
Konstantinos Venetis, Francesco Pepe, Elisabetta Munzone, Elham Sajjadi, Gianluca Russo, Pasquale Pisapia, Mariia Ivanova, Giuseppina Bonizzi, Davide Vacirca, Alessandra Rappa, Alberto Ranghiero, Sergio Vincenzo Taormina, Giuseppe Viale, Giancarlo Troncone, Massimo Barberis, Elena Guerini-Rocco, Umberto Malapelle, Nicola Fusco, Venetis, Konstantino, Pepe, Francesco, Munzone, Elisabetta, Sajjadi, Elham, Russo, Gianluca, Pisapia, Pasquale, Ivanova, Mariia, Bonizzi, Giuseppina, Vacirca, Davide, Rappa, Alessandra, Ranghiero, Alberto, Vincenzo Taormina, Sergio, Viale, Giuseppe, Troncone, Giancarlo, Barberis, Massimo, Guerini-Rocco, Elena, Malapelle, Umberto, and Fusco, Nicola
- Subjects
General Medicine ,breast cancer ,biomarkers ,PIK3CA ,NGS ,RT-PCR - Abstract
Somatic mutations in PIK3CA are present in ~40% breast cancers (BC); their detection in hormone receptor (HR)+/HER2− tumors allows for selecting patients with advanced disease eligible for PIK3CA targeting with alpelisib. The choice of what type of PIK3CA testing approach to adopt and which tissue sample to analyze is a new task in breast pathology. In this methodological study, we sought to assess the performance of next-generation sequencing (NGS) and RT-PCR for PIK3CA testing on archival formalin-fixed paraffin-embedded (FFPE) primary tumors and corresponding metastases. Sixteen HR+/HER2− BC with known PIK3CA-mutated status (ex. 7, 9, and 20) on metastatic samples by means of amplicon-based targeted NGS were selected, and n = 13 of these samples were re-tested with a commercially available CE-IVD RT-PCR assay. All available primary tumors (n = 8) were tested with both methods. NGS detected mutations in all samples, while RT-PCR in n = 2 sample-pairs and overall, in n = 5/8 (62.5%) primary tumors and 7/13 (53.8%) metastases (κ = 0.09; 95% CI, −0.69–0.87). Slight agreement (κ = 0; 95% CI, −0.59–0.59) was observed between NGS and RT-PCR, with the former being generally more sensitive in cases with low DNA quality and quantity. Post hoc visual inspection of the RT-PCR data increased the concordance to 76.9%. Targeted NGS offers reliable and robust PIK3CA testing on both tumor and metastasis FFPE samples; the accuracy of RT-PCR depends on the DNA quantity and quality. In HR+/HER2− BC, both the selection of the PIK3CA testing strategy of FFPE tissues and which sample to analyze should consider several technical parameters and should be tailored for each case.
- Published
- 2022
16. Low-risk triple-negative breast cancers: Clinico-pathological and molecular features.
- Author
-
Fusco, Nicola, Sajjadi, Elham, Venetis, Konstantinos, Ivanova, Mariia, Andaloro, Silvia, Guerini-Rocco, Elena, Montagna, Emilia, Caldarella, Pietro, Veronesi, Paolo, Colleoni, Marco, and Viale, Giuseppe
- Subjects
- *
TRIPLE-negative breast cancer , *HORMONE receptor positive breast cancer , *PROGNOSIS , *HORMONE receptors , *CLINICAL trials , *BREAST cancer - Abstract
Triple-negative breast cancers (TNBC) comprise biologically and clinically heterogeneous diseases characterized by the lack of hormone receptors (HR) and HER2 expression. This subset of tumors accounts for 15–20% of all breast cancers and pursues an ominous clinical course. However, there is a spectrum of low-risk TNBCs with no/minimal metastatic potential, including the salivary gland-type tumors, those with extensive apocrine differentiation and/or high tumor-infiltrating lymphocytes, and small-sized, early-stage (pT1a/bN0M0) TNBCs. De-escalating the treatment in low-risk TNBC, however, is not trivial because of the substantial lack of dedicated randomized clinical trials and cancer registries. The development of new diagnostic and/or prognostic biomarkers based on clinical and molecular aspects of low-risk TNBCs would lead to improved clinical treatment. Here, we sought to provide a portrait of the clinicopathological and molecular features of low-risk TNBC, with a focus on the diagnostic challenges along with the most important biological characteristics underpinning their favorable clinical course. [Display omitted] • Triple-negative breast cancers (TNBC) are commonly related to poor prognosis. • There is a spectrum of low-risk TNBCs with no/minimal metastatic potential. • Low-risk TNBC group shows a low frequency of genomic instability and indolent clinical course. • Comprehensive studies and clinical trials on low-risk TNBC patients are still lacking. • Detailed molecular characterization of low-risk TNBC may lead to tailored clinical management. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.